<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article69</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CANTOS" style="display:block; margin-bottom:10px;">CANTOS Original</a></li>
<h2><strong>CANTOS</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
    6.1 Inclusion Criteria<br/>
    6.2 Exclusion Criteria<br/>
    6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
    8.1 Primary Outcome<br/>
    8.2 Secondary Outcomes<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, lead to a lower rate of recurrent cardiovascular events in patients with a previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events compared to placebo, independent of lipid-level lowering.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff date, no guidelines have been updated to reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized, placebo-controlled trial<br/>
- N=10,061<br/>
- Intervention: Three doses of canakinumab (50 mg, 150 mg, and 300 mg injected subcutaneously every 3 months) versus placebo<br/>
- Setting: 27 centers<br/>
- Enrollment: April 2011 to March 2014<br/>
- Mean follow-up: 3.7 years<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: A composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Patients with a history of myocardial infarction and high-sensitivity C-reactive protein levels ≥2 mg per liter<br/>
- Exclusion Criteria: Chronic or recurrent infection, history of cancer except basal-cell skin carcinoma, immunocompromised state, high risk of tuberculosis, or on other systemic anti-inflammatory treatments<br/>
- Baseline Characteristics: Mean age 61 years, 25.7% female, 40.0% with diabetes<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Canakinumab: 50 mg, 150 mg, or 300 mg subcutaneous injection every 3 months<br/>
- Placebo: Subcutaneous injection every 3 months<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: The 150-mg dose showed a significant reduction in the rate of the primary efficacy endpoint compared to placebo, with hazard ratios of 0.85 (P=0.021) for the primary endpoint and 0.83 (P=0.005) for the key secondary cardiovascular endpoint that additionally included hospitalization for unstable angina leading to urgent revascularization.<br/>
- Secondary Outcomes: Canakinumab was associated with a higher incidence of fatal infections compared to placebo and did not significantly reduce all-cause mortality. There was no significant increase in the risk of neutropenia, thrombocytopenia, or hemorrhage. The cancer mortality rate was significantly lower among those receiving canakinumab.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- The trial showed a higher incidence of fatal infections with canakinumab use.<br/>
- There was no significant difference in all-cause mortality, and only the 150 mg dose met the significance threshold for the primary endpoint.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Funded by Novartis.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- The full article with additional details and results can be found at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
